12. Definitions and results of human‐anti‐mouse antibody (HAMA) evaluation in antigen‐specific antibody studies.
Study | N | Dose | Target antigen | Analysed | Positive if: | % positive | Robust if: | % robust |
Baumann 2011 | 45 | C1: 10‐10‐10‐10 μg C2: 10‐20‐50‐100 μg |
EpCAM | yes | unknown | C1: 61%, C2: 100% | ||
Berek 2001 | 252 | 2 mg | CA‐125 | yes | > 5000 ng/mL | 51% | ||
Berek 2004 | 145 | 2 mg | CA‐125 | yes | > 200 ng/mL | unknown | > 5000 ng/mL | 59% |
Berek 2009 | 371 | 2 mg | CA‐125 | yes | unknown | n.r. | ||
Braly 2009 | 40 | unknown | CA‐125 | yes | unknown | SIM vs OWD: 100% vs 80% | > 3000 ng/mL | SIM vs OWD: 88% vs 74% |
Buzzonetti 2014 | 129 | 2 mg | CA‐125 | yes; reported in Sabbatini 2013 | ||||
Ehlen 2005 | 13 | 2 mg | CA‐125 | yes | > 200 ng/mL | 100% | > 5000 ng/mL | 58% |
Gordon 2004 | 20 | 2 mg | CA‐125 | yes | > 200 ng/mL | unknown | > 5000 ng/mL | 79% |
Heiss 2010 | 129 | 10‐20‐50‐150 μg | EpCAM | yes | unknown | not reported | ||
Ma 2002 | 4 | unknown | CA‐125 | no | ||||
Method 2002 | 102 | 2 mg | CA‐125 | yes | > 200 ng/mL | unknown | unknown | 4% vs 36% vs 39% |
Möbus 2003 | 44 | 2 mg | CA‐125 | yes | > 5000 ng/mL | 68% | ||
Nicholson 2004 | 26 | 25 mg | MUC1 | no | ||||
Noujaim 2001 | 184 | 2 mg | CA‐125 | no | ||||
Pfisterer 2006 | 36 | 2 mg | CA‐125 | yes | > 15 ng/mL | L vs S: 94% vs 100% | ||
Reinartz 2004 | 119 | 2 mg | CA‐125 | yes | > 100 ng/mL | 78% | ||
Sabbatini 2006 | 42 | 2 mg/0.2 mg | CA‐125 | yes | > 100 ng/mL | 90% | ||
Sabbatini 2013 | 888 | 2 mg | CA‐125 | yes | unknown | inadequately reported | ||
Schultes 1998 | 75 | 2 mg | CA‐125 | yes | > 200 ng/mL | 90% | ||
Ströhlein 2009 | 2 | 10/20/40 μg 10/40/80 μg |
EpCAM Her2/Neu |
yes | unknown | 100% (n = 1) | ||
van Zanten‐Przybysz 2002 | 5 | 50 mg | membrane folate receptor | n.a. | ||||
Wagner 1993 | 58 | 1 mg | CA‐125 | no |
n.r.: not reported.